![logo](/logos/OSE.PA.webp)
OSE Immunotherapeutics SA
EPA:OSE.PA
7.37 (EUR) • At close July 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | OSE Immunotherapeutics SA |
Symbool | OSE.PA |
Munteenheid | EUR |
Prijs | 7.61 |
Beurswaarde | 165,542,643 |
Dividendpercentage | 0% |
52-weken bereik | 2.705 - 8.63 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Nicolas Poirier Ph.D. |
Website | https://www.ose-immuno.com |
An error occurred while fetching data.
Over OSE Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)